Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
2019-2020 INVESTORS INFORMATION
Valens GroWorks' profitable 3Q earns Buy rating: Mackie
https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/905175
Valens substantially increases annual extraction capacity to 425,000KG with plans to increase capacity to over 1,000,000KG:
https://www.prnewswire.com/news-releases/valens-substantially-increases-annual-extraction-capacity-to-425-000kg-with-plans-to-increase-capacity-to-over-1-000-000kg-300870755.html
2019 UPDATED INVESTOR PRESENTATION:
https://www.valensgroworks.com/wp-content/uploads/2019/02/VGW-Investor-Presentation-Jan-2019-V1.pdf
Extractly: An Exclusive Interview With Valens GroWorks
https://thegreenfund.com/extractly-an-exclusive-interview-with-valens-groworks?fbclid=IwAR088JGoMxXekrseKGBobMt0_Y67SMaXXod6aHxWzT2Vkl60SJq666EDf_s
Valent + BRNT ($50 Million deal)
https://stockhouse.com/news/press-releases/2019/10/30/valens-and-brnt-enter-into-major-white-label-deal-with-a-gross-revenue
SHOPPERS DRUG MART
https://stockhouse.com/news/press-releases/2019/09/16/valens-becomes-first-third-party-processor-to-enter-strategic-agreement-with
ICONIC BREWING
https://stockhouse.com/news/press-releases/2019/09/12/valens-announces-5-year-white-label-cannabis-infused-beverage-contract-with
Tantulus Lab
https://stockhouse.com/news/press-releases/2019/05/28/valens-signs-multi-year-cannabis-extraction-agreement-with-tantalus-labs
HEXO
https://stockhouse.com/news/press-releases/2019/04/25/valens-signs-multi-year-cannabis-and-hemp-extraction-agreement-with-hexo-corp
TGOD
https://stockhouse.com/news/press-releases/2019/03/11/valens-signs-multi-year-cannabis-and-hemp-extraction-agreement-with-the-green
Tilray
https://stockhouse.com/news/press-releases/2019/02/26/valens-signs-multi-year-cannabis-and-hemp-extraction-agreement-with-tilray
OGI Organigram
https://stockhouse.com/news/press-releases/2019/01/29/valens-signs-multi-year-cannabis-extraction-agreement-with-organigram
Sundial Growers
https://stockhouse.com/news/press-releases/2019/01/21/valens-signs-multi-year-cannabis-extraction-agreement-with-sundial-growers
Weed
https://stockhouse.com/news/press-releases/2018/12/13/canopy-growth-announces-multi-year-extraction-agreement-with-valens-groworks
Harvest one
https://stockhouse.com/news/press-releases/2018/11/14/valens-signs-multi-year-cannabis-extraction-and-product-r-d-agreement-with
Thanks Jim, yeah been holding my core here since the cheapies....just get a little pissed sometimes, but VGW & LABS are solid and executing....patience is needed
Just disgusted at this sector!!!
Might get it lower this sector is in bad shape..... penny flipping is all we get here now (and VGW)
LABS: List of Leading Publicly Traded Cannabis Companies by Revenue : (TSX: LABS) (OTC: MEDIF), which reports on November 12th, is expected to have generated Q3 sales of C$42 million, which would be 34% above Q2
https://www.newcannabisventures.com/list-of-leading-publicly-traded-cannabis-companies-by-revenue-expands-to-44-in-october/
Sad, I throw the towel in for now... sitting back and let my buys ride. Not adding or selling until reality kicks in
INTERVIEW: @CannabisFN CFN Media interviews
MediPharm Labs (TSX: $LABS) (OTCQX: $MEDIF) (FSE: $MLZ) President and Co-Founder Keith Strachan at Benzinga 2019 in Chicago about the company's progress and opportunities.
https://www.cannabisfn.com/cfnvideo/?id=DRlINKmk
Spot on!
Good morning MedHeads!! Let’s go
$VGW
‘Largest publicly announced multi-year white label agreement to date for a branded finished product in the Canadian cannabis industry’..
https://www.prnewswire.com/news-releases/valens-and-brnt-enter-into-major-white-label-deal-with-a-gross-revenue-potential-to-valens-of-more-than-50-million-300948613.html
Valens and BRNT Enter into Major White Label Deal with a Gross Revenue Potential to Valens of More Than $50 Million
Valens to produce a minimum of 2.2 million vape pens on behalf of BRNT Ltd. for the Canadian market over an initial two year term
Largest publicly announced multi-year white label agreement to date for a branded finished product in the Canadian cannabis industry
Gross revenue potential to Valens under the Agreement of over $50 million in the first two years, subject to final acceptance from provincial distributors, including of the proposed price per unit.
KELOWNA, BC, Oct. 30, 2019 /CNW/ - Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF) (the "Company" or "Valens"), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab is pleased to announce a multi-year white label agreement (the "Agreement") with BRNT Ltd ("BRNT"), a leading, premium, cannabis ancillary company to launch a line of unique cannabis vape pens in Canada. Under the terms of the Agreement, Valens will provide high-quality cannabis extracts, filling services and national distribution of a line of custom-formulated BRNT-branded vape pens.
Not justified to be this low? Hmmm
Hey deswag, today’s prices are doubly scrumptious don’t you think?? : )
Anybody know who is shorting this soo cheap??? 15k 20k blocks
Nice .... where’s the bottom though
Stupid easy money at these levels if buying
Yes glad I’m not heavy here, will see where I go from here....no buyers
Added some VALENS today, will add more if it bleeds....oversold, ridiculously cheap!!!
LABS is looking for future growth no doubt!
Good read thnx
Arguably one of the smartest moves investors can consider is buying an extraction-service provider.
https://www.google.com/amp/s/www.fool.com/amp/investing/2019/10/27/the-3-smartest-ways-to-invest-in-marijuana-stocks.aspx
Arguably one of the smartest moves investors can consider is buying an extraction-service provider.
https://www.google.com/amp/s/www.fool.com/amp/investing/2019/10/27/the-3-smartest-ways-to-invest-in-marijuana-stocks.aspx
The recreational market is expected to put a high demand on MediPharm, which is the largest concentrate cannabis producer in the country.
https://www.simcoe.com/news-story/9650006-oct-17-was-a-big-day-for-barrie-s-medipharm-as-edible-cannabis-became-legal/
MediPharm Labs Founders Named EY Ontario Entrepreneur of the Year Award Finalists in the Health & Life Sciences Category
FOR IMMEDIATE RELEASE
Barrie, Ontario, October 25, 2019 (GLOBE NEWSWIRE) - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce that its co-founders, Pat McCutcheon (Chairman & CEO) and Keith Strachan (Director & President), were named as finalists in the EY Ontario Entrepreneur of the Year Award in the Health & Life Sciences category. Finalists and winners were announced on October 24, 2019 in Toronto at the annual awards gala.
The EY Entrepreneur of The Year® recognizes the endeavors of exceptional people who create the products and services that keep local and global economies moving forward. Since its inception, Entrepreneur of The Year has grown and now includes programs in more than 145 cities and more than 60 countries worldwide.
“I am deeply honoured and humbled to have been named a finalist of this globally recognized award,” said Pat McCutcheon, Chairman and Chief Executive Officer of MediPharm Labs. “We began this company with a vision to change the world by harnessing the power of cannabis. I am grateful for all who trusted and believed in us along the way, especially our relentless and hard-working employees, our loyal investors and unwavering friends and family. The immense possibilities that are still to come in this rapidly evolving industry makes the future of cannabis very bright. We are all excited for what is also still to come for MediPharm Labs here in Canada and across the globe.”
“It’s been a record-paced year since recreational cannabis was legalized and we commenced sales in this new ground-breaking industry. We’ve come a long way through many hurdles. We remained steadfast in our vision, believing in ourselves and in our dream of building the best cannabis company in the world,” says Keith Strachan, Director and President of MediPharm Labs. “Being recognized and named as a finalist for the prestigious Entrepreneur of the Year award is an honour and incredible validation of the last four years. I’m looking forward to what the future holds for MediPharm Labs, we are just getting started.”
MediPharm Labs: Our Unique Story, Growing A Different Cannabis Company
Four years ago, as the Canadian cannabis industry ramped up with the growth and domination of vertically integrated cultivators, MediPharm Labs’ co-founders, Pat McCutcheon and Keith Strachan, saw an opportunity to be different. They identified a segment of the cannabis value chain they could focus on to establish a profitable business by specializing in the higher growth area of extraction and pioneering a special niche. They set a precedent with Health Canada’s application process, being the first to ever apply for a cannabis oil production license without first having a cultivation license.
While waiting for the final stages of licensing to be completed during a rigorous two-year process, the two entrepreneurs staffed the facility, developed internal protocols, modified equipment, formed partnerships, amassed dried cannabis inventory and produced extracted resin proving their readiness to deliver their first sales upon receiving their B2B sales license on November 9, 2018. They strived to maintain their independence, accepting no equity ownership from other licensed producers, assuring their ability to work with everyone in the industry as a trusted, autonomous supplier. With cannabis licence #95 from Health Canada in hand, MediPharm Labs quickly vaulted to rank among the top 5 cannabis-revenue-generators in Canada.
To keep pace with change in the industry, Pat and Keith, through their leadership, created a culture of innovation. They invested in a highly skilled team of professionals, many from the bio-pharmaceutical Industry. They also aligned with outside consultants and suppliers to optimize operations, equipment and methodologies and established a Science Advisory Committee with internationally esteemed scientists, researchers and medical professionals, who collaborate with MediPharm Labs on advancements in the emerging fields of cannabinoid extraction and cannabinoid-based derivative science.
Looking forward, MediPharm Labs has invested in R&D and strategic alliances to achieve its longer-term goal of becoming Active Pharmaceutical Ingredient provider for cannabis medicines upon completion of clinical research trials. MediPharm Labs has set its sights on new jurisdictions that have already approved medical cannabis use, actively seeking import/export opportunities, while also building their Australian subsidiary facility expected to be operational in early 2020.
MediPharm Labs was previously awarded Start-Up of the Year 2018 at the Canadian Cannabis Awards and its Australian subsidiary was the Innovation Award winner of the Australian Cannabis Industry Awards in 2019.
About Pat McCutcheon – Chairman and Chief Executive Officer
Before founding MediPharm Labs, Pat enjoyed a 15-year career in the pharmaceutical industry in top sales roles, successfully launching a wide range of medical products. He most recently worked at Janssen Pharmaceuticals (Johnson & Johnson) where he led the Hospital Division for Renal and Mental Health products. Pat brings this pharmaceutical perspective to MediPharm Labs, investing form the outset in pharma standards such as ISO rated clean rooms and critical environments and having our facility built and operating to European Good Manufacturing Practices. Pat’s foresight in creating a business that focuses on advanced cannabis concentrates bodes well for medical research, investors and consumers alike. Pat holds an HBSc (Biology) degree from the University of Western Ontario.
About Keith Strachan – Director and President
Keith Strachan co-founded MediPharm Labs in 2015, utilizing his consultancy expertise in Public Sector RFP and government contracts, compliance for government licensing and local planning, to break the mould and secure the first Health Canada Licence for cannabis oil production without first being a cultivator. A seasoned entrepreneur, Keith has applied his leadership to building out MediPharm Labs’ leading-edge facilities, launching operations and growing its workforce, while also strategically driving business development with the Company’s many supply, contract processing and white label partner LPs.
About EY Entrepreneur of the Year®
EY Entrepreneur of The Year® is the world’s most prestigious business awards program for entrepreneurs. The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global awards program of its kind, Entrepreneur Of The Year® celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries. ey.com/eoy
Institutions are buying AltaCorp etc
November 12th Pre market
That’s what she said : ) (too easy)
MediPharm Labs Supports Industry Development With Loyalist College Alliance
https://www.globenewswire.com/news-release/2019/10/23/1933882/0/en/MediPharm-Labs-Supports-Industry-Development-With-Loyalist-College-Alliance.html
UPCOMING EVENT: @MediPharmLabs Australia CEO Warren Everitt is speaking at the upcoming China HEMP CBD Industry Annual Summit 2019 in late November. For more details, check out this link: bit.ly/2P9q2Cf
Globe & Mail
From the outside, MediPharm Labs' production facility looks like another non-descript warehouse in an industrial park. The interior of the facility in Barrie, Ont., however, is a beehive of employees in white lab coats and polypropylene hair nets working inside brightly lit glass cubes. They hover over high-tech machinery with pedals and metal cylinders that turn cannabis flower into concentrate using a technique known as supercritical carbon dioxide extraction. It's not unlike making espresso coffee, with a few important distinctions. Some of these custom-made machines cost $1 million, and a single litre of the cannabis resin is worth as much as $100,000.
MediPharm Labs Corp. is not as widely known as market leaders like Canopy Growth, Aurora Cannabis or Tilray"”but it's catching up fast. It's been overlooked so far as a niche player without a multibillion dollar valuation. Unlike other cannabis companies, the firm isn't trying to manage an entire supply chain from farming to processing to marketing. Instead, as the name suggests, it's a pharmaceutical maker focused on doing one thing really well. MediPharm buys high-quality cannabis flowers from more than 20 carefully vetted suppliers, then converts them for use in recreational and medical products. "We've adopted a Swiss perspective. We work with many suppliers and sell to many customers," says Pat McCutcheon, co-founder and CEO of MediPharm Labs. In other words, they're neutral"”not passive. On the day of this interview, McCutcheon wears a dark suit with a tartan pattern and a navy tie with tiny skulls and bones, hinting at a rebellious streak.
The next chapter of pot legalization, dubbed Cannabis 2.0, will introduce new products"”such as edibles, beverages, vape pens and creams"”by mid-December of this year, all of which will be fuelled by the kind of cannabinoid-based extracts produced by MediPharm Labs. In effect, the company aims to be to cannabis what Frank Stronach's Magna International is to the global car business"”a strategic supplier of critical components that go into nearly everything its industry makes. That position in the middle of the supply chain has allowed MediPharm Labs to emerge as the biggest contract manufacturer of cannabis oil not only in Canada, but quite possibly North America and the world. Under the deal signed last month with Mississauga's TerrAscend, a seller of prescription cannabinoids, McCutcheon's firm will supply distillate worth $27 million over two years, with a potential to balloon to $192 million over three years. An agreement with the Cronos Group to supply high-quality cannabis concentrate is worth $30 million over 18 months, with the potential to double. Strategic partnerships like these have turned MediPharm Labs into the most profitable cannabis company in the country and the fourth-biggest by revenue after Canopy, Aurora and Aphria.
MediPharm's upward climb through industry ranks comes as the hype surrounding the first phase of cannabis legalization in Canada has been dampened by a few sobering realities. Virtually everyone in the industry is losing money, the threat of writedowns looms large, and the recent health controversy over vape products has caused the valuation of cannabis stocks to take a significant hit. But MediPharm reported net income of $4.1 million on revenue of $31.5 million in its latest quarter. Maybe its low-key, focused approach is exactly what the industry needs. "We don't sell mystery," explains McCutcheon, 39, noting his company's market cap is $442.8 million. The company recently switched its public listing to the TSX from the more speculative TSX Venture Exchange. "We sell fundamentals and execution."
McCutcheon worked in the medical industry for 15 years before launching his cannabis firm in 2015 with company president Keith Strachan. His last stint was at Johnson & Johnson, where he led a hospital division focused on kidney and mental health drugs. He's the company strategist, keeping an eye on the global picture. While producing resins and distillates for edibles and beverages seems lucrative today, increased competition will likely squeeze margins. McCutcheon's plan is to shift the company's focus to producing 99.9% pure ingredients for the health care market, helping to create drugs to combat everything from chronic pain to cancer.
By contrast Strachan, 34, is the regulatory brains. His background in hospital procurement and government contracts enabled his firm to land the first-ever cannabis oil production licence in Canada granted to a non-cultivator. McCutcheon and Strachan met at the Royal Victoria Regional Health Centre in Barrie, and soon recognized they had similar ambitions. Their shared pharma experience has created opportunities, including participation in a ground-breaking clinical trial for developing a non-addictive medication for opioid addiction at New York's Mount Sinai Hospital. "I like MediPharm's management team because they come from a pharmaceutical background," says analyst Scott Fortune with Roth Capital Partners in Newport Beach, Calif. "If you start from a high scientific level, it's easy to transfer that knowledge to everyday consumer products."
And a wave of consumer products is on its way. The next wave of legalization will bring branded offerings with high margins: cannabis-infused edibles like cookies and gummy worms, beverages, topical creams and vape dispensers. Conservative estimates place the value of the Canadian cannabis industry at about $6 billion by 2021 while these new products are expected to be worth about $2.7 billion, according to a recent Deloitte study. And they might also help address some of the challenges that have bedevilled the industry so far.
The sale of legal cannabis products in this country has so far been stymied by myriad factors, including the slow rollout of dispensaries in most provinces. This, in turn, has fuelled an unregulated online market for cannabis products that largely escapes enforcement. Meanwhile, licensed retailers are carefully scrutinized for compliance. "It's hard for the regulated market to compete, with all the restrictions on packaging and advertising, when the black market is allowed to operate outside the law," says Louis Barre, principal at Ottawa-based consultancy Cannab Intel. The situation is compounded by the premium paid by Canadians for legal cannabis bud"”as much as 80% above unregulated and untaxed prices. "A premium of no more than 20% is needed for the legal market to thrive," says John Kagia, chief knowledge officer at New Frontier Data in Washington, D.C.
The illegal market will have a tough time competing with the new offerings coming with Cannabis 2.0. "The next generation of products will be more effective at combating the black market because quality will be much higher," says McCutcheon. Consumers have criticized the quality of the legal bud now available at licensed dispensaries, leading them to see advantages to partaking in unlicensed options. But it's unlikely that illegal operators will be able to make the technological investment to produce these new products. MediPharm Labs' equipment was designed by biotech specialists, including GMP Engineering of Newmarket, Ont., whose clients include Pfizer, GlaxoSmithKline and Bayer. MediPharm has spent $30 million on its Barrie facility so far, and plans to spend a further $15 million to $20 million over the next 18 months.
In addition, every batch of legal cannabis oil made in this country must be analyzed by third-party labs that check for undesirable compounds including heavy metals, pesticides and residual solvents. A company must also prove that its emulsification or mixing process is sufficiently robust to distribute active ingredients evenly in, say, an edible or beverage before a product is greenlit by Health Canada.
In contrast, illegally made products have little or no quality control. Open-tank mixing by hand results in poor ingredient dispersal, and the result is product that fails to deliver consistency and predictability of experience. A much bigger problem is that the black market often uses untested additives and cutting agents. There are indications that the latest outbreak of pulmonary disease linked to vaping in the U.S. is linked to vitamin E acetate, commonly used to enrich the colour and viscosity of low-quality oils. It's sometimes safe when used in topical skin creams, but toxic when inhaled.
In American jurisdictions in which recreational cannabis products are legal, there is no shortage of stories about people either getting too high"”or not getting high at all"”from different products that report having the same dose. Analysts blame the fact that U.S. cannabis laws are made at the state rather than federal level, making standardization difficult to achieve. "Canada's rollout of Cannabis 2.0 won't be entirely smooth," says Fortune. "But it will be safe, and it's unlikely to be plagued by many of the issues we've seen in U.S. jurisdictions."
It's after 5 p.m. and McCutcheon is sitting in his new office on the 42nd floor in Toronto's financial district, winding down from another juggernaut day. It began with a 90-kilometre drive south down the highway from Barrie for meetings on Bay Street. The schedule also included discussions with a potential joint-venture partner and face time with PowerOne, one of the company's private equity investors. Over five years, McCutcheon has watched Canada's legal cannabis industry grow, but there's one thing that still surprises him. "It's the influence that capital markets have over the fundamental operations of companies," he says. "The pressure and anxiety around raising exorbitant sums of money to build facilities even before you have a licence is huge."
MediPharm Labs has been lucky in that respect. Its latest round of financing in June raised $75 million in a bought deal underwritten by a syndicate led by Scotia Capital, GMP Securities and BMO Nesbitt Burns. That same month, MediPharm Labs signed a manufacturing agreement with Toronto-based Ace Valley to potentially produce at least two million cannabis-oil vape pens over the next three years. That number could increase significantly depending on the direction the market takes.
Meanwhile, to press ahead with McCutcheon's plan to become a global supplier of specialty medicinal ingredients, MediPharm Labs will need an international footprint. The first step is opening an extraction facility in Australia later this year. "We're going to look a lot different two years from now, I guarantee it," says McCutcheon. Estimates on the size of the global medical market for cannabis products vary, but at the high end it could be worth as much as US$148 billion by 2026. Australia will be the launch pad into Thailand and South Korea for the company. Those countries are ideal partners for MediPharm Labs because they're most interested in importing finished products. The Canadian company is also working to obtain a GMP (good manufacturing practice) certification for export into the EU and Latin America. "Five years ago only four countries around the world were open to cannabis-derived medicines," says Kagia at New Frontier Data. "Today that number is more like 60 and counting."
Being able to respond to market trends is important as consumers refine their tastes. In the U.S. there's been a dramatic shift to infused products in recent years. Edibles and beverages have played a role, but vaping is the single biggest factor, accounting for 30% of a US$13.6-billion market for cannabis. "We can scale up for customer orders and build needed capacity with speed," says Strachan. That ability to execute with precision has been a big reason behind his company's rise into the front ranks of the cannabis industry. Staying there will be the challenge.
Tue, 22 Oct 2019 08:30:00 +0000
$TER $LABS
TerrAscend Canada Receives License to Sell Cannabis Extracts, Topicals and Edibles
Nice bounce back...see you guys Monday.....earnings one day closer
Let’s go green , ok guys?